JNJ Jan 2024 145.000 put
| Previous Close | 6.37 |
| Open | 6.30 |
| Bid | 6.10 |
| Ask | 6.30 |
| Strike | 145.00 |
| Expire Date | 2024-01-19 |
| Day's Range | 6.30 - 6.30 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 3.23k |
- Motley Fool
2 Unstoppable Stocks to Buy Without Hesitation Right Now
Johnson & Johnson (NYSE: JNJ) has garnered a few distinctions over the years that have set it aside from many fellow healthcare stocks, not to mention stocks in general. It has an extremely long-standing track record of not only paying out but raising its dividend, which currently yields around 3%. In fact, the company has raised its dividend every single year for six decades and counting, a period in which it's seen more than a few economic storms and cycles.
- Reuters
UPDATE 4-J&J bows out of RSV vaccine race after scrapping trial
Johnson & Johnson said it will discontinue the late-stage study of its experimental respiratory syncytial virus (RSV) adult vaccine, weeks after rivals Pfizer and GSK gained a lead in the race for the first vaccine against the virus. J&J made the decision in order "to focus on medicines with the greatest potential benefit to patients," the company said on Wednesday. The drugmaker, which started the global study in 2021 in more than 27,000 adults aged 60 years and older, did not provide any further details about the trial.
- Reuters
UPDATE 3-J&J bows out of RSV vaccine race after scrapping trial
Johnson & Johnson said it will discontinue the late-stage study of its experimental respiratory syncytial virus (RSV) adult vaccine, weeks after rivals Pfizer and GSK gained a lead in the race for the first vaccine against the virus. J&J made the decision in order to "to focus on medicines with the greatest potential benefit to patients," the company said on Wednesday. J&J, however, said it plans to share results from the late-stage study with the scientific community.
